TPI 2010 Shareholder Annual Meeting Dial-in Update

Mar 19, 2011, 12:00 ET from Tianyin Pharmaceutical Co., Inc.

CHENGDU, China, March 19, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals provides the update on dial-in information for TPI 2010 Annual Shareholder Meeting at the 26th floor, Conference Room E of 100 Wall Street near NYSE at 10:00 am (EDT) on March 21, 2011.

The Conference Dial-In information is as follows,

Dial in Number: 1-888-669-2803, Conference code: 6820951

About TPI

TPI, headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, of which 23 are listed in the national medicine reimbursement list, 7 are included in the essential drug list of China. TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:    James Jiayuan Tong M.D. Ph.D.    Chief Financial Officer, Chief Business & Development Officer    Director    Tianyin Pharmaceutical Co., Inc.    Web:     http://www.tianyinpharma.com    Email:   Dr.Tong@tianyinpharma.com    Tel:     +86-28-8551-6696 (Chengdu, China)               +86-134-3655-0011 (China)               +1-949-350-6999 (U.S.)

SOURCE Tianyin Pharmaceutical Co., Inc.



RELATED LINKS

http://www.tianyinpharma.com